Wednesday, October 27, 2021 5:00:50 PM
About a year and a half ago, Joanne Fagg published an article "Rett failure sets up thin pipeline" on evaluate.com.
She showed the status of four companies with Rett p3 trials and their status.
Pharma is a difficult business and two companies have since stopped their Rett trials.
Anavex and Acadia's Trofinetide are still continuing. Acadia's trial is for children, and should be finishing up now, as well as Anavex's Avatar adult study. Unfortunately, the Excellence-pediatric study has slipped AT LEAST well into next year. At least a year later than the article's table above shows. Competitively, schedules do matter!
Anavex's A2-73 has been shown to be superior, per analysis shown here and per Dr.Misslings corporate presentation:
Recent AVXL News
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
